A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus

M. K. Ju, S. H. Park, S. J. Kim, I. S. Moon, Y. S. Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Enteric-coated mycophenolate sodium (Myfortic, Novartis Pharma AG, Basel, Switzerland) is designed to improve the gastrointestinal tolerability of micophenolic acid. This study was designed to evaluate the efficacy and safety of Myfortic in Korean de novo renal transplantation. A total of 65 patients from four transplantation centers received the study drug at least once and were included in the intention-to-treat analysis. This study was an open-label, single-arm, multicenter trial with 6-month patient follow-up. Patients received 360 mg (body weight < 50 kg) or 720 mg (body weight > 50 kg) of Myfortic per day with tacrolimus and steroids. Induction therapy included basiliximab. The incidence of biopsy-confirmed acute rejection (primary endpoint) within 6 months after transplantation was 7/65 (10.8%). There were 2 (3.1%) graft losses due to severe acute rejection and 1 (1.5%) patient-death due to cardiac arrest. Twenty-two (38.8%) patients experienced gastrointestinal discomfort; however, only 3 (4.5%) cases were associated with an apparent drug reaction. Seventeen (25.4%) patients underwent dose adjustment or Myfortic discontinuation during the study period. Patient and graft survival rates at 6 months posttransplantation were 98.1% and 97.0%. Myfortic with tacrolimus-based immunosuppression was efficient and safe after de novo renal transplantation in Korean patients.

Original languageEnglish
Pages (from-to)144-146
Number of pages3
JournalTransplantation Proceedings
Volume44
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Mycophenolic Acid
Tacrolimus
Multicenter Studies
Transplants
Kidney
Safety
Kidney Transplantation
Transplantation
Intention to Treat Analysis
Clinical Studies
Graft Survival
Heart Arrest
Switzerland
Pharmaceutical Preparations
Immunosuppression
Survival Rate
Steroids
Body Weight
Biopsy
Acids

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

@article{2d387fa9ba984088a218aaf20184b113,
title = "A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus",
abstract = "Enteric-coated mycophenolate sodium (Myfortic, Novartis Pharma AG, Basel, Switzerland) is designed to improve the gastrointestinal tolerability of micophenolic acid. This study was designed to evaluate the efficacy and safety of Myfortic in Korean de novo renal transplantation. A total of 65 patients from four transplantation centers received the study drug at least once and were included in the intention-to-treat analysis. This study was an open-label, single-arm, multicenter trial with 6-month patient follow-up. Patients received 360 mg (body weight < 50 kg) or 720 mg (body weight > 50 kg) of Myfortic per day with tacrolimus and steroids. Induction therapy included basiliximab. The incidence of biopsy-confirmed acute rejection (primary endpoint) within 6 months after transplantation was 7/65 (10.8{\%}). There were 2 (3.1{\%}) graft losses due to severe acute rejection and 1 (1.5{\%}) patient-death due to cardiac arrest. Twenty-two (38.8{\%}) patients experienced gastrointestinal discomfort; however, only 3 (4.5{\%}) cases were associated with an apparent drug reaction. Seventeen (25.4{\%}) patients underwent dose adjustment or Myfortic discontinuation during the study period. Patient and graft survival rates at 6 months posttransplantation were 98.1{\%} and 97.0{\%}. Myfortic with tacrolimus-based immunosuppression was efficient and safe after de novo renal transplantation in Korean patients.",
author = "Ju, {M. K.} and Park, {S. H.} and Kim, {S. J.} and Moon, {I. S.} and Kim, {Y. S.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.transproceed.2011.12.015",
language = "English",
volume = "44",
pages = "144--146",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus

AU - Ju, M. K.

AU - Park, S. H.

AU - Kim, S. J.

AU - Moon, I. S.

AU - Kim, Y. S.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Enteric-coated mycophenolate sodium (Myfortic, Novartis Pharma AG, Basel, Switzerland) is designed to improve the gastrointestinal tolerability of micophenolic acid. This study was designed to evaluate the efficacy and safety of Myfortic in Korean de novo renal transplantation. A total of 65 patients from four transplantation centers received the study drug at least once and were included in the intention-to-treat analysis. This study was an open-label, single-arm, multicenter trial with 6-month patient follow-up. Patients received 360 mg (body weight < 50 kg) or 720 mg (body weight > 50 kg) of Myfortic per day with tacrolimus and steroids. Induction therapy included basiliximab. The incidence of biopsy-confirmed acute rejection (primary endpoint) within 6 months after transplantation was 7/65 (10.8%). There were 2 (3.1%) graft losses due to severe acute rejection and 1 (1.5%) patient-death due to cardiac arrest. Twenty-two (38.8%) patients experienced gastrointestinal discomfort; however, only 3 (4.5%) cases were associated with an apparent drug reaction. Seventeen (25.4%) patients underwent dose adjustment or Myfortic discontinuation during the study period. Patient and graft survival rates at 6 months posttransplantation were 98.1% and 97.0%. Myfortic with tacrolimus-based immunosuppression was efficient and safe after de novo renal transplantation in Korean patients.

AB - Enteric-coated mycophenolate sodium (Myfortic, Novartis Pharma AG, Basel, Switzerland) is designed to improve the gastrointestinal tolerability of micophenolic acid. This study was designed to evaluate the efficacy and safety of Myfortic in Korean de novo renal transplantation. A total of 65 patients from four transplantation centers received the study drug at least once and were included in the intention-to-treat analysis. This study was an open-label, single-arm, multicenter trial with 6-month patient follow-up. Patients received 360 mg (body weight < 50 kg) or 720 mg (body weight > 50 kg) of Myfortic per day with tacrolimus and steroids. Induction therapy included basiliximab. The incidence of biopsy-confirmed acute rejection (primary endpoint) within 6 months after transplantation was 7/65 (10.8%). There were 2 (3.1%) graft losses due to severe acute rejection and 1 (1.5%) patient-death due to cardiac arrest. Twenty-two (38.8%) patients experienced gastrointestinal discomfort; however, only 3 (4.5%) cases were associated with an apparent drug reaction. Seventeen (25.4%) patients underwent dose adjustment or Myfortic discontinuation during the study period. Patient and graft survival rates at 6 months posttransplantation were 98.1% and 97.0%. Myfortic with tacrolimus-based immunosuppression was efficient and safe after de novo renal transplantation in Korean patients.

UR - http://www.scopus.com/inward/record.url?scp=84863361094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863361094&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.12.015

DO - 10.1016/j.transproceed.2011.12.015

M3 - Article

C2 - 22310600

AN - SCOPUS:84863361094

VL - 44

SP - 144

EP - 146

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1

ER -